Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (123)
July 12, 2010
- Maurer's Healthcare Insight (122)
May 31, 2010
- Maurer's Healthcare Insight (121)
May 3, 2010
- Maurer's Healthcare Insight (120)
April 12, 2010
- Maurer's Healthcare Insight (119)
March 1, 2010
- Maurer's Healthcare Insight (118)
January 4, 2010
- Maurer's Healthcare Insight (117)
December 14, 2009
- Maurer's Healthcare Insight (116)
November 30, 2009
- Maurer's Healthcare Insight (115)
November 16, 2009
- Maurer's Healthcare Insight (114)
October 26, 2009
- Maurer's Healthcare Insight (113)
October 5, 2009
- Maurer's Healthcare Insight (112)
September 14, 2009
- Maurer's Healthcare Insight (111)
August 24, 2009
- Maurer's Healthcare Insight (110)
July 27, 2009
- Maurer's Healthcare Insight (109)
June 22, 2009
- Maurer's Healthcare Insight (108)
May 18, 2009
- Maurer's Healthcare Insight (107)
April 27, 2009
- Maurer's Healthcare Insight (106)
March 30, 2009
- Maurer's Healthcare Insight (105)
March 2, 2009
- Maurer's Healthcare Insight (104)
January 26, 2009
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…